Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 6/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18937351 | 0.88 | CYP4F2 (0.41) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL354482 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11MEN1KMT2APKM | |
| Ammonia Solution, Strong SCHEMBL27920586 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL2563173 | 0.79 | CYP4F2 (0.37) | CYP4F2CYP4A11TSHRPPARA | |
| SCHEMBL27924507 | 0.76 | CYP4F2 (0.48) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL354404 | 0.75 | CYP4F2 (0.36) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL28134678 | 0.74 | CYP4F2 (0.67) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL3289027 | 0.74 | CYP4F2 (0.92) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL18050593 | 0.73 | ALDH1A1 (0.43) | CYP4F2CYP4A11MEN1KMT2APKM | |
| SCHEMBL23906719 | 0.73 | CYP4F2 (0.46) | CYP4F2CYP4A11MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B9 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560976-B1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-08-24 | — | — | EP | disclosed |
| CN-103025738-B | Furopyridine compound and uses thereof | NOVARTIS AG (CH) | 2015-08-19 | — | — | CN | disclosed |
| CN-103025738-A | Furopyridine compounds and uses thereof | NOVARTIS AG | 2013-04-03 | — | — | CN | disclosed |
| EP-2560976-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324239-B2 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015907-A1 | Furopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131709-A1 | FUROPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015907-A1 | Furopyridine compounds and uses thereof | CYP3A5, QDPR, DPYD | CYP4F2 13/4885CYP4A11 186/4885MEN1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.